GlobeNewsWire · 8 Oct 2026positive
Nexalin Technology said it regained compliance with Nasdaq’s minimum bid price requirement, and a Nasdaq Hearings Panel granted its request for continued listing. The company said it remains focused on transitioning toward commercial revenue generation and advancing its U.S. clinical programs.
Why it matters — The update addresses NXL’s Nasdaq listing status and outlines the company’s stated commercial and clinical priorities.
GlobeNewsWire · 1 Oct 2026positive
Nexalin Technology has signed a definitive exclusive distribution and local manufacturing agreement for Brazil and South America, covering seven countries and more than 300 million people. The agreement includes an initial 100-device commercialization program for its ANVISA-approved Nexalin Sync device, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers.
Why it matters — This marks a significant step in Nexalin's transition toward commercial revenue generation, expanding access to its ANVISA-approved device across South America while establishing a foundation for larger strategic deals.
GlobeNewsWire · 29 Sept 2026positive
Nexalin Technology announced the appointment of Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15, 2026. DiTota, who spent over two decades in neuromodulation at Abbott and Medtronic, will help Nexalin develop distribution relationships, go-to-market plans, and commercial infrastructure to convert its existing regulatory approvals in China, Brazil, Oman, and Israel into commercial sales.
Why it matters — The appointment signals Nexalin's move from clinical development toward commercialization of its DIFS platform, bringing experienced neuromodulation leadership to help convert its regulatory approvals into actual sales across the US, Europe, and South America.
GlobeNewsWire · 3 Sept 2026positive
Nexalin Technology announced a new secondary analysis of data from its previously published randomized, sham-controlled clinical trial, revealing previously unreported improvements in memory, comprehension, and language function in Alzheimer's patients. The company said the ADAS-Cog subscale analysis will help guide the design of its planned U.S. Alzheimer's pilot study.
Why it matters — For NXL watchers, this analysis highlights new, previously unreported cognitive benefits from the company's trial data and directly informs the design of its upcoming U.S. Alzheimer's pilot study.
GlobeNewsWire · 27 Aug 2026neutral
Nexalin Technology's board of directors approved a 1-for-30 reverse stock split of the company's common stock to ensure continued compliance with the Nasdaq bid-price rule. Stockholders had previously approved future reverse stock splits, their timing, and granted the board authority to determine exact split ratios.
Why it matters — The reverse stock split is aimed at keeping Nexalin's stock in compliance with Nasdaq listing requirements, which is a significant corporate action that could affect the company's share price and listing status.
